Regulation and role of CAMKK2 in prostate cancer

Thomas L. Pulliam, Pavithr Goli, Dominik Awad, Chenchu Lin, Sandi R. Wilkenfeld, Daniel E. Frigo

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


In 2011, CAMKK2, the gene encoding calcium/calmodulin-dependent kinase kinase 2 (CAMKK2), was demonstrated to be a direct target of the androgen receptor and a driver of prostate cancer progression. Results from multiple independent studies have confirmed these findings and demonstrated the potential role of CAMKK2 as a clinical biomarker and therapeutic target in advanced prostate cancer using a variety of preclinical models. Drug development efforts targeting CAMKK2 have begun accordingly. CAMKK2 regulation can vary across disease stages, which might have important implications in the use of CAMKK2 as a biomarker. Moreover, new non-cell-autonomous roles for CAMKK2 that could affect tumorigenesis, metastasis and possible comorbidities linked to disease and treatment have emerged and could present novel treatment opportunities for prostate cancer.

Original languageEnglish (US)
Pages (from-to)367-380
Number of pages14
JournalNature Reviews Urology
Issue number6
StatePublished - Jun 2022


  • Calcium-Calmodulin-Dependent Protein Kinase Kinase/genetics
  • Cell Line, Tumor
  • Cell Transformation, Neoplastic
  • Humans
  • Male
  • Prostate/pathology
  • Prostatic Neoplasms/genetics

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Regulation and role of CAMKK2 in prostate cancer'. Together they form a unique fingerprint.

Cite this